POLARITYTE, INC. Form 8-K May 01, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 1, 2018

POLARITYTE, INC.

(Exact name of registrant as specified in its charter)

Delaware 000-51128 06-1529524 (State or other jurisdiction (Commission (IRS Employer

of incorporation) File Number) Identification No.)

1960 S. 4250 West

Salt Lake City, UT 84104

Edgar Filing: POLARITYTE, INC. - Form 8-K

(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (385) 237-2279
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[]Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securitie Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company []
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []

Item 8.01 Other Events.

On May 1, 2018, PolarityTE, Inc., issued a press release entitled "PolarityTETM Regenerates Complex, Hierarchically-Organized, Corticocancellous Bone in Preclinical Studies," updating results from its preclinical studies on OsteoTETM.

Item 9.01 Financial Statements and Exhibits

Exhibits

Included with this report as Exhibit 99.1 is the release entitled "PolarityTETM Regenerates Complex, Hierarchically-Organized, Corticocancellous Bone in Preclinical Studies," dated May 1, 2018.

Forward-Looking Statements

The Company cautions you that statements included in this Current Report on Form 8-K that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believe "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, among other things, references to the closing of the offering and the expected net proceeds therefrom. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the risk and uncertainties associated with market conditions and the satisfaction of customary closing conditions relating to the offering, as well as risks and uncertainties in the Company's business, including those risks described in the Company's periodic reports it files with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

POLARITYTE, INC.

Dated: May 1, 2018 /s/ John Stetson
John Stetson
Chief Financial Officer

3